Glucagon-like peptide-1 receptor agonist variant and method

Modified GLP-1R agonists with reduced immunogenicity, achieved through site-directed pegylation, address the challenges of immunogenicity and frequency of administration, providing effective glucose control and weight loss with improved adherence and stability.

JP2026517773APending Publication Date: 2026-06-02NEWLY INC
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
NEWLY INC
Filing Date
2024-04-30
Publication Date
2026-06-02

Smart Images

  • Figure 2026517773000105
    Figure 2026517773000105
  • Figure 2026517773000106
    Figure 2026517773000106
  • Figure 2026517773000107
    Figure 2026517773000107
Patent Text Reader

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs having one or more amino acids substituted to reduce immunogenicity and antigenicity are described. These GLP-1R agonists and analogs have comparable or better physicochemical properties and pharmacokinetics in mammalian hosts compared to GLP-1RAs currently available for treatment. Compositions and formulations of these agonist peptides are particularly suitable for treating, mitigating, and / or preventing one or more metabolic disorders, e.g., obesity, diabetes mellitus, and non-alcoholic fatty liver disease, as well as one or more neurodegenerative diseases, e.g., Alzheimer's disease (AD) and Parkinson's disease (PD).
Need to check novelty before this filing date? Find Prior Art